Evidence map›Paper›PMID 30416680›Full record

ArticleOncotarget2018

The Cockayne syndrome protein B is involved in the repair of 5-AZA-2'-deoxycytidine-induced DNA lesions.

Estefanía Burgos-Morón, José Manuel Calderón-Montaño, Nuria Pastor, Andreas Höglund, Ángel Ruiz-Castizo, Inmaculada Domínguez, Miguel López-Lázaro, Nabil Hajji, Thomas Helleday, Santiago Mateos and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Estefanía Burgos-MorónDepartment of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.
José Manuel Calderón-MontañoDepartment of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.
Nuria PastorDepartment of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain.
Andreas HöglundScience for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
Ángel Ruiz-CastizoDepartment of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain.
Inmaculada DomínguezDepartment of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain.
Miguel López-LázaroDepartment of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.
Nabil HajjiDepartment of Medicine, Division of Experimental Medicine, Centre for Pharmacology & Therapeutics, Toxicology Unit, Imperial College London, Hammersmith Campus, London, W12 0NN UK.
Thomas HelledayScience for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
Santiago MateosDepartment of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain.
Manuel Luis OrtaDepartment of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain.
Universidad de Sevilla · ESHammersmith Hospital · GBKarolinska Institutet · SEScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Cockayne Syndrome Protein B (CSB) plays an essential role in Transcription-Coupled Nucleotide Excision Repair (TC-NER) by recruiting repair proteins once transcription is blocked with a DNA lesion. In fact, CSB-deficient cells are unable to recover from transcription-blocking DNA lesions. 5-Aza-2'-deoxycytidine (5-azadC) is a nucleoside analogue that covalently traps DNA methyltransferases (DNMTs) onto DNA. This anticancer drug has a double mechanism of action: it reverts aberrant hypermethylation in tumour-suppressor genes, and it induces DNA damage. We have recently reported that Homologous Recombination and XRCC1/PARP play an important role in the repair of 5-azadC-induced DNA damage. However, the mechanisms involved in the repair of the DNMT adducts induced by azadC remain poorly understood. In this paper, we show for the first time the importance of CSB in the repair of azadC-induced DNA lesions. We propose a model in which CSB initiates a signalling pathway to repair transcription blocks induced by incorporated 5-azadC. Indeed, CSB-deficient cells treated with 5-azadC show a delay in the repair of trapped DNMT1, increased levels of DNA damage and reduced survival.

Indexed as

5-azadCCSBDNA damageDNMT1transcription

Identifiers

PMID30416680
PMCPMC6205548
OpenAlexW2896762673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.